文献速递造血干细胞移植与细胞治疗

在外周血单倍体移植中,移植后环磷酰胺联合抗胸腺细胞球蛋白对比单用移植后环磷酰胺的影响:代表欧洲血液与骨髓移植学会细胞治疗与免疫生物学工作组的一项回顾性研究

Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation.
PubMed 文献 · Br J Haematol · 2025-08-07

中位随访29.80个月,多因素校正后,PTCy+ATG组总生存(OS)和无复发生存(RFS)较低(HR均为1.18),但慢性移植物抗宿主病(cGVHD)较少(HR=0.68)。

要点

  • PTCy+ATG组2年cGVHD累积发生率18.5%,低于PTCy单用组的28.4%(p<0.001)。
  • 多因素校正后,PTCy+ATG组OS较低(HR=1.18,p=0.037),RFS较低(HR=1.18,p=0.027)。
  • PTCy+ATG组cGVHD发生率较低(HR=0.68,p=0.004),但OS和RFS较差。

核心结论

  • 在这项回顾性分析中,在单倍体造血细胞移植中,PTCy联合ATG用于GVHD预防与cGVHD减少相关,但也与较差的OS和RFS相关。

研究设计与样本

  • 代表欧洲血液与骨髓移植学会(EBMT)细胞治疗与免疫生物学工作组的回顾性研究,分析EBMT登记库中2014年至2021年间因血液恶性肿瘤接受外周血单倍体造血细胞移植的患者。

主要发现

  • 单因素分析中,PTCy单用组 vs PTCy+ATG组的2年GRFS分别为40.5% vs 37.5%(p=0.098),RFS分别为50.9% vs 45.8%(p=0.015),OS分别为56.9% vs 52.5%(p=0.01),复发累积发生率分别为24.2% vs 28.1%(p=0.032),NRM分别为25% vs 26.1%(p=0.49),cGVHD累积发生率分别为28.4% vs 18.5%(p<0.001)。
  • aGVHD在两组间无差异。
  • 多因素校正后,PTCy+ATG组OS较低(HR=1.18,p=0.037),RFS较低(HR=1.18,p=0.027),cGVHD较少(HR=0.68,p=0.004)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the setting of haploidentical haematopoietic cell transplantation (HCT), post-transplant cyclophosphamide (PTCy) has dramatically reduced the incidence of graft-versus-host disease (GVHD) and non-relapse mortality. To further reduce GVHD incidence, the addition of antithymocyte globulin (ATG) to PTCy was evaluated in retrospective and non-comparative prospective studies showing promising results. We conducted a large retrospective analysis of the European Society for Blood and Marrow Transplantation (EBMT) registry to evaluate this approach. We analysed haploHCT with peripheral blood stem cells performed for haematological malignancies between 2014 and 2021. GVHD prophylaxis included either PTCy alone or PTCy+ATG. Four thousand five hundred and nineteen patients were analysed in the PTCy only group versus 675 with PTCy+ATG. Median follow-up was 29.80 months. In univariate analysis, 2-year GVHD-free, relapse-free survival (GRFS), relapse-free survival (RFS), overall survival (OS), cumulative incidence of relapse, non-relapse mortality (NRM) and chronic GvHD (cGVHD) were, respectively: 40.5% versus 37.5% (p = 0.098), 50.9% versus. 45.8% (p = 0.015), 56.9% versus 52.5% (p = 0.01), 24.2% versus 28.1% (p = 0.032), 25% versus 26.1% (p = 0.49) and 28.4% versus 18.5% (p < 0.001). aGVHD did not differ. After multivariable adjustment, OS and RFS were lower in the PTCy+ATG group: HR = 1.18 (p = 0.037) and HR = 1.18 (p = 0.027) and patients receiving PTCy+ATG had less cGVHD: HR = 0.68 (p = 0.004). In that retrospective analysis, the addition of ATG to PTCy for GVHD prophylaxis in haploHCT was associated with a reduction of cGVHD but also a worse OS and RFS.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Capes A, Mooyaart JE, Blaise D, et al. Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2025. PMID: 40772384. doi:10.1111/bjh.70050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。